Information on EC 1.1.1.95 - phosphoglycerate dehydrogenase and Organism(s) Homo sapiens

3-phosphoglycerate dehydrogenase

3-phosphoglyceric acid dehydrogenase

-

A10

-

alpha-phosphoglycerate dehydrogenase

-

D-3-phosphoglycerate dehydrogenase

D-3-phosphoglycerate:NAD oxidoreductase

-

dehydrogenase, phosphoglycerate

-

glycerate 3-phosphate dehydrogenase

-

glycerate-1,3-phosphate dehydrogenase

-

PGDH

Phgdh

phosphoglycerate oxidoreductase

-

phosphoglyceric acid dehydrogenase

-

type 1 D-3-phosphoglycerate dehydrogenase

-

Biosynthesis of secondary metabolites, Cysteine and methionine metabolism, Glycine, serine and threonine metabolism, Methane metabolism, Microbial metabolism in diverse environments

oxidation

-

redox reaction

-

reduction

-

BRENDA

serine metabolism

KEGG

-

-, -

3-phospho-D-glycerate:NAD+ 2-oxidoreductase

This enzyme catalyses the first committed and rate-limiting step in the phosphoserine pathway of serine biosynthesis. The reaction occurs predominantly in the direction of reduction. The enzyme from the bacterium Escherichia coli also catalyses the activity of EC 1.1.1.399, 2-oxoglutarate reductase [6].

9075-29-0

-

2-oxoglutarate + NADH + H+

D-2-hydroxyglutarate + NAD+

-

-

?

3-phospho-D-glycerate + NAD+

3-phosphonooxypyruvate + NADH + H+

-

737315, 737556

-

?

3-phospho-D-glycerate + NAD+

3-phosphooxypyruvate + NADH + H+

7 entries

3-phosphooxypyruvate + acetylpyridine

3-phospho-D-glycerate + ?

-

-

r

3-phosphooxypyruvate + NADH + H+

3-phospho-D-glycerate + NAD+

3-phosphooxypyruvate + pyridinealdehyde adenine dinucleotide

3-phospho-D-glycerate + ?

-

-

r

3-phosphooxypyruvate + thionicotinamide

3-phospho-D-glycerate + ?

-

-

r

oxaloacetate + NADH + H+

malate + NAD+

-

-

?

phosphonooxypyruvate + NADH + H+

?

-

-

?

additional information

?

-

2-oxoglutarate + NADH + H+

D-2-hydroxyglutarate + NAD+

-

-

?

3-phospho-D-glycerate + NAD+

3-phosphonooxypyruvate + NADH + H+

-

737315, 737556

-

?

3-phospho-D-glycerate + NAD+

3-phosphooxypyruvate + NADH + H+

5 entries

oxaloacetate + NADH + H+

malate + NAD+

-

-

?

phosphonooxypyruvate + NADH + H+

?

-

-

?

additional information

?

-

NAD+

4 entries

NADH

(2,3-dihydro-1H-benzotriazol-1-yl)(4-phenylpiperazin-1-yl)methanone

0.1 mM, 37% inhibition

-

(3,4-dichlorophenyl)(morpholin-4-yl)methanethione

0.1 mM, 96% inhibition

-

(3R)-N-(4,6-dimethylpyridin-2-yl)-3-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

-

(3R,5S)-N-(4,6-dimethylpyridin-2-yl)-3,5-dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

-

(3S)-N-(4,6-dimethylpyridin-2-yl)-3-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

-

(4-methylpyridin-2-yl)[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methanethione

-

-

1-(2,4-dichlorophenyl)-2-morpholino-2-thioxoethan-1-one

-

-

1-(2-bromophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

-

-

1-(2-chlorophenyl)-1H-pyrrole-2,5-dione

0.1 mM, 78% inhibition

-

1-(4-bromophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

-

-

1-(4-chlorophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

-

-

1-(4-chlorophenyl)-2-morpholino-2-thioxoethan-1-one

-

-

1-(4-fluorophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

-

-

1-(4-iodophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

-

-

1-(4-methoxybenzene-1-sulfonyl)piperazine

0.1 mM, 35% inhibition

-

2-(4-methylpiperidin-1-yl)-1-phenyl-2-thioxoethan-1-one

-

-

2-(4-methylpyridin-2-yl)-1-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1-thione

-

-

2-(morpholin-4-yl)-1-(3-nitrophenyl)-2-sulfanylideneethan-1-one

-

-

2-(morpholin-4-yl)-1-(4-nitrophenyl)-2-sulfanylideneethan-1-one

-

-

2-(morpholin-4-yl)-1-phenyl-2-sulfanylideneethan-1-one

-

-

2-chloro-4-(5-[(Z)-[2-(ethylcarbamothioyl)hydrazinylidene]methyl]furan-3-yl)benzoic acid

i.e. PKUMDL-WQ-2101, specifically binds to the enzyme (PHGDH) in PHGDH-amplified breast cancer cells with EC50 values less than 0.010 mM in serine-replete media. Mainly inhibits PHGDH activity by forming hydrogen-bond networks with R134, K57, and T59 of site I and T59, T56, and K57 of site II, respectively

-

2-morpholino-1-phenyl-2-thioxoethan-1-one

-

-

2-phenylmorpholine

0.1 mM, 61% inhibition

-

3-pentyl-5,5-diphenylimidazolidine-2,4-dione

0.1 mM, 25% inhibition

-

3-phosphooxypyruvate

3-[(E)-(5-cyano-2-hydroxy-4-methyl-6-oxo-1,6-dihydropyridin-3-yl)diazenyl]benzoic acid

i.e. PKUMDL-WQ-2201, specifically binds to the enzyme (PHGDH) in PHGDH-amplified breast cancer cells with EC50 values less than 0.010 mM in serine-replete media. Mainly inhibits PHGDH activity by forming hydrogen-bond networks with R134, K57, and T59 of site I and T59, T56, and K57 of site II, respectively

-

4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine

0.1 mM, 46% inhibition

-

4-benzyl-N-(4,6-dimethylpyridin-2-yl)piperazine-1-carbothioamide

-

-

4-benzyl-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carbothioamide

0.1 mM, 80% inhibition

-

4-chloro-N-(2-nitrophenyl)benzamide

0.1 mM, 59% inhibition

-

4-[(1S)-1-[(5-chloro-6-[2-[(2-hydroxyethyl)amino]-2-oxoethoxy]-1H-indole-2-carbonyl)amino]-2-hydroxyethyl]benzoic acid

competitive, i.e. SPR Kd

-

4-[(2-chlorophenyl)methyl]-N-(4,6-dimethylpyridin-2-yl)piperazine-1-carbothioamide

-

-

4-[(3-chlorophenyl)methyl]-N-(4,6-dimethylpyridin-2-yl)piperazine-1-carbothioamide

-

-

4-[(4,6-dimethylpyridin-2-yl)carbamothioyl]-1-[[4-(trifluoromethyl)phenyl]methyl]piperazine-2-carboxylic acid

-

-

4-[(4-bromophenyl)methyl]-N-(4,6-dimethylpyridin-2-yl)piperazine-1-carbothioamide

-

-

4-[3-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide

-

-

5-[(2-furanylcarbonyl)amino]-3-methyl-4-thiocyanato-2-thiophenecarboxylic acid ethyl ester

i.e. CBR-5884, covalent inhibitor that binds to a Cys in the non-active site and disrupts its oligomeric state. CBR-5884 inhibits the growth of cells by 35% to 60% in serine-abundant media, and by 80% to 90% in serine-depleted media at 0.030 mM

-

adenosine 5'-diphosphoribose

0.12 mM, 50% inhibition. NAD+ competitive inhibitor

azacoccone E

non-competitive inhibitor in a time-dependent manner

-

BI-4916

-

-

cyclohexa-2,5-diene-1,4-dione

0.1 mM, 100% inhibition

ethyl 5-[(furan-2-carbonyl)amino]-3-methyl-4-(nitrilo-lambda4-sulfanyl)thiophene-2-carboxylate

noncompetitive, i.e. CBR-5884

-

ixocarpalactone A

non-competitive inhibitor relative to the substrate of NAD coenzyme

-

L-serine

-

methyl 2-([4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioyl]amino)pyridine-4-carboxylate

-

-

morpholino(phenyl)methanethione

-

-

N'-(4,6-dimethylpyridin-2-yl)-N-methyl-N-[2-(methyl[[4-(trifluoromethyl)phenyl]methyl]amino)ethyl]thiourea

-

-

N-(3-methylphenyl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)(oxo)[4-(trifluoromethyl)phenyl]ethanethioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-3-(hydroxymethyl)-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-3-([[4-(trifluoromethyl)phenyl]methyl]amino)piperidine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-3-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-3-phenyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-3-[3-(trifluoromethyl)anilino]piperidine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-3-[4-(trifluoromethyl)anilino]piperidine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-(2-methoxyphenyl)piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-(3-methoxyphenyl)piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-(4-(trifluoromethyl)benzyl)piperazine-1-carbothioamide

i.e. NCT-503, non-competitive inhibitor in regards to substrates and cofactors, closely binds to the active site

-

N-(4,6-dimethylpyridin-2-yl)-4-(4-methoxyphenyl)piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-(pyridin-2-yl)piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-(pyridin-3-yl)piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-(pyridin-4-yl)piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(2-fluorophenyl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(2-methylphenyl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(3-fluorophenyl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(3-methylphenyl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(4-fluorophenyl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(4-methylphenyl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(pyridin-2-yl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(pyridin-3-yl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[(pyridin-4-yl)methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[2-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[2-[4-(trifluoromethyl)phenyl]ethyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[3-(trifluoromethyl)anilino][1,4'-bipiperidine]-1'-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[3-(trifluoromethyl)benzoyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[4-(trifluoromethyl)anilino][1,4'-bipiperidine]-1'-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[4-(trifluoromethyl)benzoyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[4-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[6-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[[3-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[[4-(trifluoromethoxy)phenyl]methyl]piperazine-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[[4-(trifluoromethyl)phenyl]methyl]-1,4-diazepane-1-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

-

N-(4,6-dimethylpyridin-2-yl)-5-[[4-(trifluoromethyl)phenyl]methyl]hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carbothioamide

-

-

N-(4,6-dimethylpyridin-2-yl)-N'-[2-(methyl[[4-(trifluoromethyl)phenyl]methyl]amino)ethyl]thiourea

-

-

N-(4,6-dimethylpyridin-2-yl)-N'-[2-([[4-(trifluoromethyl)phenyl]methyl]amino)ethyl]thiourea

-

-

N-(4,6-dimethylpyridin-2-yl)[4-(trifluoromethyl)phenyl]ethanethioamide

-

-

N-(4,6-dimethylpyrimidin-2-yl)-4-nitrobenzamide

0.1 mM, 13% inhibition

-

N-(4-methylpyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(4-methylpyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide

-

-

N-(4-methylpyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carboximidamide

-

-

N-(4-methylquinolin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(diphenylmethyl)-4-nitrobenzamide

0.1 mM, 54% inhibition

-

N-(pyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(pyridin-3-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(pyridin-4-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-(quinolin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-cyclohexyl-N'-phenylthiourea

0.1 mM, 28% inhibition

-

N-methyl-N-(4-methylpyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-morpholinobenzenesulfonamide

-

-

N-[(pyridin-2-yl)methyl]-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

-

-

N-[1'-[(4,6-dimethylpyridin-2-yl)carbamothioyl][1,4'-bipiperidin]-4-yl]-3-(trifluoromethyl)benzamide

-

-

N-[1-[(4,6-dimethylpyridin-2-yl)carbamothioyl]piperidin-3-yl]-4-(trifluoromethyl)benzamide

-

-

naphthalene-1,4-dione

0.1 mM, 95% inhibition

phenyl cyclohexylcarbamodithioate

0.1 mM, 51% inhibition

-

[4-[(4,6-dimethylpyridin-2-yl)carbamothioyl]piperazin-1-yl]methyl 2-methoxybenzoate

-

-

[4-[(4,6-dimethylpyridin-2-yl)carbamothioyl]piperazin-1-yl]methyl 3-methoxybenzoate

-

-

[4-[(4,6-dimethylpyridin-2-yl)carbamothioyl]piperazin-1-yl]methyl 4-methoxybenzoate

-

-

additional information

4 entries

-

10.1

2-oxoglutarate

-

at pH 7.6 and 37°C

0.003 - 0.294

3-phospho-D-glycerate

6 entries

0.015 - 0.0216

3-phosphohydroxypyruvate

0.0393

acetylpyridine

pH 7.5, temperature not specified in the publication

-

0.0053 - 0.15

NAD+

4 entries

0.004

NADH

6.5

oxaloacetate

-

at pH 7.6 and 37°C

0.1477

pyridinealdehyde adenine dinucleotide

pH 7.5, temperature not specified in the publication

-

0.0118

Thionicotinamide

pH 7.5, temperature not specified in the publication

additional information

-

0.078

2-oxoglutarate

-

at pH 7.6 and 37°C

0.075 - 311

3-phospho-D-glycerate

0.017

acetylpyridine

pH 7.5, temperature not specified in the publication

-

0.005

NAD+

pH 7.5, temperature not specified in the publication

0.177

oxaloacetate

-

at pH 7.6 and 37°C

0.0035

pyridinealdehyde adenine dinucleotide

pH 7.5, temperature not specified in the publication

-

0.0075

Thionicotinamide

pH 7.5, temperature not specified in the publication

2400 - 14000

3-phospho-D-glycerate

0.057 - 0.063

L-serine

0.016

(3,4-dichlorophenyl)(morpholin-4-yl)methanethione

Homo sapiens

pH 8.8, 25°C

-

0.012

(3R)-N-(4,6-dimethylpyridin-2-yl)-3-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0099

(3S)-N-(4,6-dimethylpyridin-2-yl)-3-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.077

1-(2,4-dichlorophenyl)-2-morpholino-2-thioxoethan-1-one

Homo sapiens

pH 8.5, temperature not specified in the publication

-

0.1607

1-(2-bromophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

Homo sapiens

pH 8.8, 25°C

-

0.1307

1-(4-bromophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

Homo sapiens

pH 8.8, 25°C

-

0.00987

1-(4-chlorophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

Homo sapiens

pH 8.8, 25°C

-

0.0203

1-(4-chlorophenyl)-2-morpholino-2-thioxoethan-1-one

Homo sapiens

pH 8.5, temperature not specified in the publication

-

0.0689

1-(4-fluorophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

Homo sapiens

pH 8.8, 25°C

-

0.1777

1-(4-iodophenyl)-2-(morpholin-4-yl)-2-sulfanylideneethan-1-one

Homo sapiens

pH 8.8, 25°C

-

0.0851

2-(4-methylpiperidin-1-yl)-1-phenyl-2-thioxoethan-1-one

Homo sapiens

pH 8.5, temperature not specified in the publication

-

0.0881

2-(morpholin-4-yl)-1-(3-nitrophenyl)-2-sulfanylideneethan-1-one

Homo sapiens

pH 8.8, 25°C

-

0.0351

2-(morpholin-4-yl)-1-(4-nitrophenyl)-2-sulfanylideneethan-1-one

Homo sapiens

pH 8.8, 25°C

-

0.0309

2-(morpholin-4-yl)-1-phenyl-2-sulfanylideneethan-1-one

Homo sapiens

pH 8.8, 25°C

-

0.111

2-morpholino-1-phenyl-2-thioxoethan-1-one

Homo sapiens

pH 8.5, temperature not specified in the publication

-

0.04

4-benzyl-N-(4,6-dimethylpyridin-2-yl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0752

4-chloro-N-(2-nitrophenyl)benzamide

Homo sapiens

pH 8.8, 25°C

-

0.02

4-[(2-chlorophenyl)methyl]-N-(4,6-dimethylpyridin-2-yl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.011

4-[(3-chlorophenyl)methyl]-N-(4,6-dimethylpyridin-2-yl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.033

4-[(4,6-dimethylpyridin-2-yl)carbamothioyl]-1-[[4-(trifluoromethyl)phenyl]methyl]piperazine-2-carboxylic acid

Homo sapiens

pH 8.0, 22°C

-

0.017

4-[(4-bromophenyl)methyl]-N-(4,6-dimethylpyridin-2-yl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0064 - 0.037

4-[3-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide

-

0.033

5-[(2-furanylcarbonyl)amino]-3-methyl-4-thiocyanato-2-thiophenecarboxylic acid ethyl ester

Homo sapiens

pH and temperature not specified in the publication

-

0.0098

azacoccone E

Homo sapiens

pH and temperature not specified in the publication

-

0.00166

ixocarpalactone A

Homo sapiens

pH and temperature not specified in the publication

-

0.013

methyl 2-([4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioyl]amino)pyridine-4-carboxylate

Homo sapiens

pH 8.0, 22°C

-

0.106

morpholino(phenyl)methanethione

Homo sapiens

pH 8.5, temperature not specified in the publication

-

0.0073

N'-(4,6-dimethylpyridin-2-yl)-N-methyl-N-[2-(methyl[[4-(trifluoromethyl)phenyl]methyl]amino)ethyl]thiourea

Homo sapiens

pH 8.0, 22°C

-

0.01

N-(4,6-dimethylpyridin-2-yl)(oxo)[4-(trifluoromethyl)phenyl]ethanethioamide

Homo sapiens

pH 8.0, 22°C

-

0.0058

N-(4,6-dimethylpyridin-2-yl)-3-(hydroxymethyl)-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.012

N-(4,6-dimethylpyridin-2-yl)-3-([[4-(trifluoromethyl)phenyl]methyl]amino)piperidine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0083

N-(4,6-dimethylpyridin-2-yl)-3-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.031

N-(4,6-dimethylpyridin-2-yl)-3-phenyl-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0072

N-(4,6-dimethylpyridin-2-yl)-3-[3-(trifluoromethyl)anilino]piperidine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0057 - 0.01

N-(4,6-dimethylpyridin-2-yl)-3-[4-(trifluoromethyl)anilino]piperidine-1-carbothioamide

-

0.024

N-(4,6-dimethylpyridin-2-yl)-4-(2-methoxyphenyl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.014

N-(4,6-dimethylpyridin-2-yl)-4-(3-methoxyphenyl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0025

N-(4,6-dimethylpyridin-2-yl)-4-(4-(trifluoromethyl)benzyl)piperazine-1-carbothioamide

Homo sapiens

pH and temperature not specified in the publication

-

0.016

N-(4,6-dimethylpyridin-2-yl)-4-(4-methoxyphenyl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.037

N-(4,6-dimethylpyridin-2-yl)-4-(pyridin-2-yl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.05

N-(4,6-dimethylpyridin-2-yl)-4-(pyridin-3-yl)piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.041

N-(4,6-dimethylpyridin-2-yl)-4-[(2-fluorophenyl)methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0092

N-(4,6-dimethylpyridin-2-yl)-4-[(2-methylphenyl)methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.039

N-(4,6-dimethylpyridin-2-yl)-4-[(3-fluorophenyl)methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.02

N-(4,6-dimethylpyridin-2-yl)-4-[(3-methylphenyl)methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.038

N-(4,6-dimethylpyridin-2-yl)-4-[(4-fluorophenyl)methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.015 - 0.017

N-(4,6-dimethylpyridin-2-yl)-4-[(4-methylphenyl)methyl]piperazine-1-carbothioamide

-

0.05

N-(4,6-dimethylpyridin-2-yl)-4-[(pyridin-2-yl)methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.059

N-(4,6-dimethylpyridin-2-yl)-4-[(pyridin-4-yl)methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0087

N-(4,6-dimethylpyridin-2-yl)-4-[2-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.023

N-(4,6-dimethylpyridin-2-yl)-4-[2-[4-(trifluoromethyl)phenyl]ethyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0065

N-(4,6-dimethylpyridin-2-yl)-4-[3-(trifluoromethyl)anilino][1,4'-bipiperidine]-1'-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.022

N-(4,6-dimethylpyridin-2-yl)-4-[3-(trifluoromethyl)benzoyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0063

N-(4,6-dimethylpyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0077

N-(4,6-dimethylpyridin-2-yl)-4-[4-(trifluoromethyl)anilino][1,4'-bipiperidine]-1'-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.019

N-(4,6-dimethylpyridin-2-yl)-4-[4-(trifluoromethyl)benzoyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0043

N-(4,6-dimethylpyridin-2-yl)-4-[4-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0037

N-(4,6-dimethylpyridin-2-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.011

N-(4,6-dimethylpyridin-2-yl)-4-[6-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0063

N-(4,6-dimethylpyridin-2-yl)-4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0053

N-(4,6-dimethylpyridin-2-yl)-4-[[3-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.011

N-(4,6-dimethylpyridin-2-yl)-4-[[4-(trifluoromethoxy)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0073 - 0.008

N-(4,6-dimethylpyridin-2-yl)-4-[[4-(trifluoromethyl)phenyl]methyl]-1,4-diazepane-1-carbothioamide

-

0.0025

N-(4,6-dimethylpyridin-2-yl)-4-[[4-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.016

N-(4,6-dimethylpyridin-2-yl)-5-[[4-(trifluoromethyl)phenyl]methyl]hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.021

N-(4,6-dimethylpyridin-2-yl)-N'-[2-(methyl[[4-(trifluoromethyl)phenyl]methyl]amino)ethyl]thiourea

Homo sapiens

pH 8.0, 22°C

-

0.0097

N-(4,6-dimethylpyridin-2-yl)-N'-[2-([[4-(trifluoromethyl)phenyl]methyl]amino)ethyl]thiourea

Homo sapiens

pH 8.0, 22°C

-

0.015

N-(4,6-dimethylpyridin-2-yl)[4-(trifluoromethyl)phenyl]ethanethioamide

Homo sapiens

pH 8.0, 22°C

-

0.0153

N-(4-methylpyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.021

N-(4-methylquinolin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0069

N-(pyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0089

N-(pyridin-3-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.014

N-(pyridin-4-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.01

N-(quinolin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.0921

N-morpholinobenzenesulfonamide

Homo sapiens

pH 8.5, temperature not specified in the publication

-

0.021

N-[(pyridin-2-yl)methyl]-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Homo sapiens

pH 8.0, 22°C

-

0.011

N-[1'-[(4,6-dimethylpyridin-2-yl)carbamothioyl][1,4'-bipiperidin]-4-yl]-3-(trifluoromethyl)benzamide

Homo sapiens

pH 8.0, 22°C

-

0.0087

N-[1-[(4,6-dimethylpyridin-2-yl)carbamothioyl]piperidin-3-yl]-4-(trifluoromethyl)benzamide

Homo sapiens

pH 8.0, 22°C

-

0.03

[4-[(4,6-dimethylpyridin-2-yl)carbamothioyl]piperazin-1-yl]methyl 3-methoxybenzoate

Homo sapiens

pH 8.0, 22°C

-

0.026

[4-[(4,6-dimethylpyridin-2-yl)carbamothioyl]piperazin-1-yl]methyl 4-methoxybenzoate

Homo sapiens

pH 8.0, 22°C

-

7.1

assay at

25

assay at

-

high expression levels in the proliferative phase

skin-derived

-

-

drug target

malfunction

metabolism

physiological function

O43175 pBLAST

SERA_HUMAN

533

0

56651

Swiss-Prot

other Location (Reliability: 2)

A0A2C9F2M7 pBLAST

A0A2C9F2M7_HUMAN

532

0

56112

TrEMBL

other Location (Reliability: 2)

A0A286YF22 pBLAST

A0A286YF22_HUMAN

526

0

55939

TrEMBL

other Location (Reliability: 2)

V9HW79 pBLAST

V9HW79_HUMAN

533

0

56665

TrEMBL

other Location (Reliability: 2)

19 entries

207300

-

analytical ultracentrifugation

56800

4 * 56800

57200

-

dimer

-

homotetramer

additional information

sitting drop vapour diffusion method, cocrystal structure of catalytic subunit of the enzyme (PHGDHs) with NAD+ and L-tartrate reveals a domain movement upon substrate binding

A373T

naturally occuring mutation located in the nucleotide binding and regulatory domains of 3-PGDH, the mutation does not affect steady-state expression, protein stability, and protein degradation rates, the mutant is almost catalytically inactive

G377S

naturally occuring mutation located in the nucleotide binding and regulatory domains of 3-PGDH, the mutation does not affect steady-state expression, protein stability, and protein degradation rates, the mutant is almost catalytically inactive

R135W

naturally occuring mutation located in the nucleotide binding and regulatory domains of 3-PGDH, the mutation does not affect steady-state expression, protein stability, and protein degradation rates, the mutant is almost catalytically inactive

V261M

naturally occuring mutation located in the nucleotide binding and regulatory domains of 3-PGDH, the mutation does not affect steady-state expression, protein stability, and protein degradation rates, the mutant is almost catalytically inactive

V425M

naturally occuring mutation in the carboxy-terminal regulatory domain, leads to 3-PGDH deficiency, the mutant is almost catalytically inactive

V490M

naturally occuring mutation in the carboxy-terminal regulatory domain, leads to 3-PGDH deficiency, the mutant is almost catalytically inactive

additional information

-

Talon cobalt based immobilized metal affinity column chromatography

-

expressed in Escherichia coli BL21(DE3) cells

-

expressed in HEK-293T cells

-

expression in Escherichia coli Rosetta (DE3) pLysS competent cells

gene PHGDH consists of 12 exons and maps to chromosome 1p12, enzyme expression analysis in fibroblasts, transient overexpression of FLAG-tagged wild-type and mutant enzymes in HEK-293 cells

HOXA10 is required for enzyme regulation in the endometrium, HOAX antisense expression, siRNA, causes a 4.4fold upregulation of 3-PGDH in endometrial cells

701170

HOXA10 is required for enzyme regulation in the endometrium, HOAX sense expression causes a 2.0fold downregulation of 3-PGDH in endometrial cells

701170

the enzyme is highly expressed in tumors as a result of amplification, transcription, or its degradation and stability alteration, which dysregulates the serine biosynthesis pathway via metabolic enzyme activity to nourish tumors. High expression of the enzyme is dramatically related to tumor resistance to chemotherapies

molecular biology

-

results demonstrate that the promoter activity of the human PHGDH gene is positively regulated by the action of transcription factors Sp1 and NF-Y

686940

Jun, d.o..Y.; Park, H.S.; Lee, J.Y.; Baek, J.Y.; Park, H.K.; Fukui, K.; Kim, Y.H.

Positive regulation of promoter activity of human 3-phosphoglycerate dehydrogenase (PHGDH) gene is mediated by transcription factors Sp1 and NF-Y

Gene

414

106-114

2008

Homo sapiens

18378410

698067

Furuya, S.; Yoshida, K.; Kawakami, Y.; Yang, J.H.; Sayano, T.; Azuma, N.; Tanaka, H.; Kuhara, S.; Hirabayashi, Y.

Inactivation of the 3-phosphoglycerate dehydrogenase gene in mice: changes in gene expression and associated regulatory networks resulting from serine deficiency

Funct. Integr. Genomics

8

235-249

2008

Homo sapiens, Mus musculus

18228065

Tabatabaie, L.; de Koning, T.J.; Geboers, A.J.; van den Berg, I.E.; Berger, R.; Klomp, L.W.

Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics

Hum. Mutat.

30

749-756

2009

Homo sapiens (O43175), Homo sapiens

19235232

701170

Du, H.; Vitiello, D.; Sarno, J.; Taylor, H.

3-Phosphoglycerate dehydrogenase (3-PGDH) expression is regulated by HOXA10 in murine endometrium and human endometrial cells

Reproduction

139

237-245

2009

Homo sapiens (O43175), Homo sapiens, Mus musculus (Q61753), Mus musculus

19778996

Fan, J.; Teng, X.; Liu, L.; Mattaini, K.R.; Looper, R.E.; Vander Heiden, M.G.; Rabinowitz, J.D.

Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate

ACS Chem. Biol.

10

510-516

2015

Homo sapiens

25406093

Xu, X.L.; Chen, S.; Salinas, N.D.; Tolia, N.H.; Grant, G.A.

Comparison of type 1 D-3-phosphoglycerate dehydrogenases reveals unique regulation in pathogenic Mycobacteria

Arch. Biochem. Biophys.

570

32-39

2015

Bacillus subtilis, Corynebacterium glutamicum, Homo sapiens, Mycobacterium marinum, Mycobacterium tuberculosis, Mycolicibacterium smegmatis, Streptomyces coelicolor (Q9Z564)

25698123

Rohde, J.M.; Brimacombe, K.R.; Liu, L.; Pacold, M.E.; Yasgar, A.; Cheff, D.M.; Lee, T.D.; Rai, G.; Baljinnyam, B.; Li, Z.; Simeonov, A.; Hall, M.D.; Shen, M.; Sabatini, D.M.; Boxer, M.B.

Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors

Bioorg. Med. Chem.

26

1727-1739

2018

Homo sapiens (O43175), Homo sapiens

29555419

763090

Grant, G.A.

D-3-Phosphoglycerate dehydrogenase

Front. Mol. Biosci.

5

110

2018

Escherichia coli (C3SVM7), Escherichia coli, Rattus norvegicus (O08651), Homo sapiens (O43175), Homo sapiens, Mycobacterium tuberculosis (P9WNX3), Mycobacterium tuberculosis, Mycobacterium tuberculosis ATCC 25618 (P9WNX3)

30619878

Zhao, X.; Fu, J.; Du, J.; Xu, W.

The role of D-3-phosphoglycerate dehydrogenase in Cancer

Int. J. Biol. Sci.

16

1495-1506

2020

Homo sapiens (O43175), Homo sapiens

32226297

Ravez, S.; Corbet, C.; Spillier, Q.; Dutu, A.; Robin, A.D.; Mullarky, E.; Cantley, L.C.; Feron, O.; Frederick, R.

alpha-Ketothioamide derivatives a promising tool to interrogate phosphoglycerate dehydrogenase (PHGDH)

J. Med. Chem.

60

1591-1597

2017

Homo sapiens (O43175)

28085281

Unterlass, J.E.; Wood, R.J.; Basle, A.; Tucker, J.; Cano, C.; Noble, M.M.E.; Curtin, N.J.

Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH)

Oncotarget

8

104478-104491

2017

Homo sapiens (O43175), Homo sapiens

29262655